AstraZeneca’s Calquence approved in the EU for the treatment of most common type of leukaemia in adults
The FINANCIAL -- AstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union ...
